Building on the endogenous regulatory role of CCN3 on CCN2, a set of small modified peptides based on two CCN3 regions identified as responsible for this activity have been created by BLR Bio, as potential agents to treat fibrotic diseases including cancer [24]. Here, CCN3 is linked to cancer.